Sep. 3 at 5:12 PM
$RCKT I like a few particular stocks for either thier drug being best in class or diferentiated from standard of care. I also like some stocks for FDA related delays like CRLs. So
$ACHV aids in quitting nicotine with all the vaping their is potentially a bigger market for this drug than was availble for chantix. Price target 15 dollars. FDA approval date june 2026
$MIST reiceved crl replied and FDA accepted PUDFA Date Dec 2025
$BMEA has been decimated by short selling and exit of ceo yet data is remarkable in Subtype of type 2 diabetes SIDD. Still have a trial in type 1 . Combo trial with ozempic that showed addtional 10% weight loss above ozempic alone. A potentiallyh best in class GLP1 drug more efficacious and safer than current approved drugs. And Nich drug BMF500 in Subtype of AML that beats standard of care hands down.
$DNLI proprietry delivery system that delivers payloads across blood brain barrier FDA approval date later this year for Hunters disease . Will be best in class.
